Pancreatic Cancer Research

ResearcherInsermActive in the last 2 years

Thierry Conroy

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-7548-284X; OpenAlex author ID A5020997210. Sources: OpenAlex.

Their work

Papers
48 (first author 4, last author 8)
Trials
0
Grants
0
Labs led
1
Collaborators
212
Papers, trials and grants by year

2011: 3 papers · 2012: 1 paper · 2013: 2 papers · 2014: 1 paper · 2015: none · 2016: 3 papers · 2017: 2 papers · 2018: 4 papers · 2019: 4 papers · 2020: 2 papers · 2021: 3 papers · 2022: 4 papers · 2023: 5 papers · 2024: 5 papers · 2025: 3 papers · 2026: 6 papers

Papers 48

  1. ESMO Clinical Practice Guideline Express Update on daraxonrasib in the treatment of metastatic pancreatic cancer. Co-author DOI 10.1016/j.annonc.2026.08.003↗
  2. Pancreatic cancer. Co-author DOI 10.1038/s41572-026-00699-6↗
  3. Impact of Positive Resection Margins on Recurrence and Survival After Resection and Adjuvant Chemotherapy in Pancreatic Cancer: Results of the PRODIGE 24-CCTG … Last author DOI 10.1097/sla.0000000000006449↗
  4. Deep Learning of Histopathology Predicts Outcomes After Surgery for Pancreatic Cancer. Co-author DOI 10.1200/cci-25-00268↗
  5. Impact of Tumor Genomic Profile on Adjuvant Chemotherapy Efficacy in Resected Pancreatic Adenocarcinoma: Results From the PRODIGE-24/CCTG PA6 Study. First author DOI 10.1200/jco-25-02508↗
  6. Developing a Histology-Based Artificial Intelligence Biomarker to Predict Adjuvant Chemotherapy Benefit in Pancreatic Cancer. Co-author DOI 10.1200/jco-26-00327↗
  7. ESMO Clinical Practice Guideline Express Update on the management of metastatic pancreatic cancer. Co-author DOI 10.1016/j.esmoop.2025.104528↗
  8. Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with pancreatic cancer. First author DOI 10.1016/j.esmoop.2025.105826↗
  9. Glycation Stress–Driven Transcriptomic Signature Predicts Survival Benefit from Adjuvant Gemcitabine in Resectable Pancreatic Cancer Co-author DOI 10.1101/2025.07.07.663493↗
  10. Reply to the Letter to the Editor 'Radiation therapy for locally advanced pancreatic adenocarcinoma: a therapeutic option which should not be forgotten' (in re… Co-author DOI 10.1016/j.annonc.2024.05.004↗
  11. Development and validation of AI-assisted transcriptomic signatures to personalize adjuvant chemotherapy in patients with pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.annonc.2024.06.010↗
  12. Reply to 'NALIRIFOX in the frontline for metastatic pancreatic cancer: evidence beyond NAPOLI 3'. First author DOI 10.1038/s41571-024-00953-4↗
  13. Prediction of Adjuvant Gemcitabine Sensitivity in Resectable Pancreatic Adenocarcinoma Using the GemPred RNA Signature: An Ancillary Study of the PRODIGE-24/CC… Co-author DOI 10.1200/jco.22.02668↗
  14. Role of molecular biology in the management of pancreatic cancer. Co-author DOI 10.4251/wjgo.v16.i7.2902↗
  15. Overall Survival With Adjuvant mFOLFIRINOX for Pancreatic Cancer-Reply. Co-author DOI 10.1001/jamaoncol.2022.7361↗
  16. Pancreatic cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Co-author DOI 10.1016/j.annonc.2023.08.009↗
  17. Tumor Growth Rate Informs Treatment Efficacy in Metastatic Pancreatic Adenocarcinoma: Application of a Growth and Regression Model to Pivotal Trial and Real-Wo… Co-author DOI 10.1093/oncolo/oyac217↗
  18. Adjuvant and neoadjuvant approaches in pancreatic cancer. Co-author DOI 10.1097/cco.0000000000000962↗
  19. Effect of Adapted Physical Activity in Patients With Advanced Pancreatic Cancer: The APACaP GERCOR Randomized Trial. Co-author DOI 10.6004/jnccn.2023.7065↗
  20. Consensus Statement on Mandatory Measurements for Pancreatic Cancer Trials for Patients With Resectable or Borderline Resectable Disease (COMM-PACT-RB): A Syst… Co-author DOI 10.1001/jamaoncol.2022.0168↗
  21. Five-Year Outcomes of FOLFIRINOX vs Gemcitabine as Adjuvant Therapy for Pancreatic Cancer: A Randomized Clinical Trial. Co-author DOI 10.1001/jamaoncol.2022.3829↗
  22. Preneoplastic Lesions in Surgical Specimens Do Not Worsen the Prognosis of Patients Who Underwent Surgery for Pancreatic Adenocarcinoma: Post-Hoc Analysis of t… Co-author DOI 10.3390/cancers14163945↗
  23. Development of a Clinical-Biological Model to Assess Tumor Progression in Metastatic Pancreatic Cancer: Post Hoc Analysis of the PRODIGE4/ACCORD11 Trial. Co-author DOI 10.3390/cancers14205068↗
  24. Gemcitabine plus nab-paclitaxel versus FOLFIRINOX for unresected pancreatic cancer: Comparative effectiveness and evaluation of tumor growth in Veterans. Co-author DOI 10.1053/j.seminoncol.2021.02.001↗
  25. Future directions in drug development in pancreatic cancer. First author DOI 10.1053/j.seminoncol.2021.02.002↗
  26. Neoadjuvant Treatment Strategies in Resectable Pancreatic Cancer. Last author DOI 10.3390/cancers13184724↗
  27. Metastatic Pancreatic Cancer: ASCO Guideline Update. Co-author DOI 10.1200/jco.20.01364↗
  28. Primary Thromboprophylaxis in Pancreatic Cancer Patients: Why Clinical Practice Guidelines Should Be Implemented. Co-author DOI 10.3390/cancers12030618↗
  29. Combination or single-agent chemotherapy as adjuvant treatment for pancreatic cancer? Co-author DOI 10.1016/s1470-2045(19)30107-x↗
  30. Systemic treatment of pancreatic cancer revisited. Last author DOI 10.1053/j.seminoncol.2018.12.003↗
  31. Adjuvant treatment of pancreatic cancer. Co-author DOI 10.1097/cco.0000000000000546↗
  32. An update on treatment options for pancreatic adenocarcinoma. Last author DOI 10.1177/1758835919875568↗
  33. Pancreatic cancer: French clinical practice guidelines for diagnosis, treatment and follow-up (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, ACHBT, AFC). Co-author DOI 10.1016/j.dld.2018.08.008↗
  34. Consensus statement on mandatory measurements in pancreatic cancer trials (COMM-PACT) for systemic treatment of unresectable disease. Co-author DOI 10.1016/s1470-2045(18)30098-6↗
  35. Chemotherapy for pancreatic cancer: the rise of multidrug regimens. Last author DOI 10.1016/s2468-1253(18)30235-8↗
  36. FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer. Co-author DOI 10.1056/nejmoa1809775↗
  37. Current status on the place of FOLFIRINOX in metastatic pancreatic cancer and future directions. Last author DOI 10.1177/1756283x17713879↗
  38. Response to FOLFIRINOX by gender in patients with metastatic pancreatic cancer: Results from the PRODIGE 4/ ACCORD 11 randomized trial. Last author DOI 10.1371/journal.pone.0183288↗
  39. Current standards and new innovative approaches for treatment of pancreatic cancer. Co-author DOI 10.1016/j.ejca.2015.12.026↗
  40. FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis. Co-author DOI 10.1016/s1470-2045(16)00172-8↗
  41. An assessment of the benefit-risk balance of FOLFIRINOX in metastatic pancreatic adenocarcinoma. Co-author DOI 10.18632/oncotarget.12761↗
  42. Guidelines for time-to-event end-point definitions in trials for pancreatic cancer. Results of the DATECAN initiative (Definition for the Assessment of Time-to… Co-author DOI 10.1016/j.ejca.2014.07.011↗
  43. The role of the FOLFIRINOX regimen for advanced pancreatic cancer. Co-author DOI 10.1007/s11912-012-0290-4↗
  44. Impact of FOLFIRINOX compared with gemcitabine on quality of life in patients with metastatic pancreatic cancer: results from the PRODIGE 4/ACCORD 11 randomize… Last author DOI 10.1200/jco.2012.44.4869↗
  45. New strategies and designs in pancreatic cancer research: consensus guidelines report from a European expert panel. Co-author DOI 10.1093/annonc/mdr351↗
  46. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. Co-author DOI 10.1056/nejmoa1011923↗
  47. Metastatic pancreatic cancer: old drugs, new paradigms. Co-author DOI 10.1097/cco.0b013e3283473610↗
  48. [Chemotherapy of metastatic pancreatic adenocarcinoma: challenges and encouraging results]. Co-author DOI 10.1684/bdc.2011.1494↗

Closest collaborators

The 25 strongest of 212 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Michel Pierre Ducreux · 17 shared papers, 2011–2026 · strength 3.36
  2. Aurélien Lambert · 15 shared papers, 2016–2026 · strength 2.64
  3. Pascal R. Hammel · 11 shared papers, 2012–2026 · strength 1.56
  4. James Biagi · 8 shared papers, 2018–2026 · strength 1.45
  5. Jerome F. Cros · 7 shared papers, 2024–2026 · strength 1.43
  6. Rémy Nicolle · 6 shared papers, 2024–2026 · strength 1.15
  7. Alexandre Harlé · 5 shared papers, 2022–2026 · strength 0.98
  8. Jean‐Baptiste Bachet · 9 shared papers, 2011–2026 · strength 0.96
  9. Anthony Turpin · 4 shared papers, 2024–2026 · strength 0.74
  10. Daniel John Renouf · 4 shared papers, 2024–2026 · strength 0.74
  11. Nelson Dusetti · 4 shared papers, 2024–2026 · strength 0.74
  12. Jean‐Luc Van Laethem · 7 shared papers, 2012–2022 · strength 0.65
  13. Emmanuel Mitry · 6 shared papers, 2011–2026 · strength 0.62
  14. Juan Iovanna · 4 shared papers, 2012–2026 · strength 0.57
  15. Eileen Mary O'Reilly · 4 shared papers, 2018–2026 · strength 0.54
  16. Vinciane Rebours · 3 shared papers, 2024–2026 · strength 0.51
  17. Ignacio Garrido‐Laguna · 2 shared papers, 2020–2024 · strength 0.45
  18. David Malka · 5 shared papers, 2014–2019 · strength 0.41
  19. Alice Chia-Chi Wei · 3 shared papers, 2018–2026 · strength 0.41
  20. Olivier Bouché · 5 shared papers, 2011–2024 · strength 0.41
  21. Jens Thomas Siveke · 3 shared papers, 2018–2026 · strength 0.40
  22. Chris Nevala-Plagemann · 1 shared paper, 2024 · strength 0.36
  23. Marc Ychou · 6 shared papers, 2011–2023 · strength 0.36
  24. Lilian Schwarz · 3 shared papers, 2018–2021 · strength 0.35
  25. Nicolas Alejandro Fraunhoffer · 2 shared papers, 2024–2026 · strength 0.35

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.